Value
4.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 4.0 |
MANE · Why this verdict
Why Veradermics (MANE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Veradermics carries a favorable risk/reward with approximately 16.8% upside to the price target and analyst consensus implying roughly 37% appreciation potential, but the entire thesis rests on a single pipeline asset against a quality profile well below sustainable levels — a setup suited only for a small, cautious position sized for the binary risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The investment case depends entirely on a single pipeline candidate (VDPHL01), meaning any clinical setback or development delay would materially impair the thesis without diversification to absorb the impact. Bear case | The company expands its active pipeline to more than 1 clinical-stage program within 18 months, reducing the binary single-asset dependency. | →Stable |
| CounterA focused single-asset approach allows the company to allocate resources with maximum intensity toward one program; if the candidate advances successfully, the concentrated exposure is entirely rewarding. | ||
Across margins, moat, and balance-sheet productivity, business quality is well below the level a sustainable franchise requires — consistent with a company whose value lies entirely in future pipeline outcomes rather than current earnings power. Quality breakdown | Operating income turns positive for 2 consecutive quarters, signaling early commercial traction. | →Stable |
| CounterFor a pipeline-stage biotechnology company, sub-threshold quality scores are expected; the investment is a call on program advancement, and current income metrics are irrelevant to the thesis. | ||
Analyst consensus carries a price target approximately 37% above the current price, reflecting expectations that pipeline progress has not yet been priced into the stock. Sentiment breakdown | Price closes within 15% of the analyst consensus target within 12 months as pipeline catalysts materialize. | →Stable |
| CounterCoverage is light at only 4 analysts, meaning a single estimate revision can swing the consensus target significantly, and the signal is easily distorted by thin coverage. | ||
With approximately 16.8% upside to the price target against 14.3% downside, the reward-to-risk ratio is roughly 2.4-to-1 — favorable geometry that justifies a small initial position while awaiting pipeline clarity. Price targets | Price advances at least 10% toward the price target within 12 months without breaching the downside level. | →Stable |
| CounterMomentum indicators remain below the level required to confirm an uptrend, and with a range-bound technical setup, the favorable geometry may not convert into actual gains without a near-term catalyst. | ||
The investment case depends entirely on a single pipeline candidate (VDPHL01), meaning any clinical setback or development delay would materially impair the thesis without diversification to absorb the impact.
→StableBear case
- Expectation
- The company expands its active pipeline to more than 1 clinical-stage program within 18 months, reducing the binary single-asset dependency.
CounterA focused single-asset approach allows the company to allocate resources with maximum intensity toward one program; if the candidate advances successfully, the concentrated exposure is entirely rewarding.
Across margins, moat, and balance-sheet productivity, business quality is well below the level a sustainable franchise requires — consistent with a company whose value lies entirely in future pipeline outcomes rather than current earnings power.
→StableQuality breakdown
- Expectation
- Operating income turns positive for 2 consecutive quarters, signaling early commercial traction.
CounterFor a pipeline-stage biotechnology company, sub-threshold quality scores are expected; the investment is a call on program advancement, and current income metrics are irrelevant to the thesis.
Analyst consensus carries a price target approximately 37% above the current price, reflecting expectations that pipeline progress has not yet been priced into the stock.
→StableSentiment breakdown
- Expectation
- Price closes within 15% of the analyst consensus target within 12 months as pipeline catalysts materialize.
CounterCoverage is light at only 4 analysts, meaning a single estimate revision can swing the consensus target significantly, and the signal is easily distorted by thin coverage.
With approximately 16.8% upside to the price target against 14.3% downside, the reward-to-risk ratio is roughly 2.4-to-1 — favorable geometry that justifies a small initial position while awaiting pipeline clarity.
→StablePrice targets
- Expectation
- Price advances at least 10% toward the price target within 12 months without breaching the downside level.
CounterMomentum indicators remain below the level required to confirm an uptrend, and with a range-bound technical setup, the favorable geometry may not convert into actual gains without a near-term catalyst.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.3 |
| Price target | 6.8 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (5.0) — signal dampened
Insider
5.1/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.2 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 1.1 |
| 52w position | 9.4 |
Risk (lower is worse)
5.7/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 5.7 |
| days to cover | 6.9 |
| volatility | 0.0 |
| debt equity | 10.0 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.0/10data confidence 25%| Component | Sub-score |
|---|---|
| erm | 5.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.2>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.1=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.13
Upside
-1.9%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $4.9B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 6.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.1=NEGATIVE.
The strongest dimensions are Sentiment at 6.5, Momentum at 6.2, and Peer rank at 6.2; the weakest are Quality at 2.5, Technical at 3.5, and Value at 4.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.13 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The investment case depends entirely on a single pipeline candidate (VDPHL01), meaning any clinical setback or development delay would materially impair the thesis without diversification to absorb the impact.
Trip ifCompany expands its active pipeline to more than 1 clinical-stage program within 18 months.
- P2Across margins, moat, and balance-sheet productivity, business quality is well below the level a sustainable franchise requires — consistent with a company whose value lies entirely in future pipeline outcomes rather than current earnings power.
Trip ifOperating income rises above $0 for 2 consecutive quarters, indicating the business has begun developing the earnings power needed for a sustainable investment-grade franchise.
- P3Analyst consensus carries a price target approximately 37% above the current price, reflecting expectations that pipeline progress has not yet been priced into the stock.
Trip ifAnalyst consensus price target is revised to less than $105, implying less than 10% upside from the current price of $96.27.
- P4With approximately 16.8% upside to the price target against 14.3% downside, the reward-to-risk ratio is roughly 2.4-to-1 — favorable geometry that justifies a small initial position while awaiting pipeline clarity.
Trip ifUpside to the price target falls below 5% from current levels, reducing the reward-to-risk ratio below 1.0-to-1.